Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 21.58B |
| Revenue (ttm) | 2.88B |
| Net Income (ttm) | 4.05B |
| Shares Out | 29.76M |
| EPS (ttm) | 134.05 |
| PE Ratio | 5.38 |
| Forward PE | 50.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,900 |
| Open | 720.08 |
| Previous Close | 720.11 |
| Day's Range | 713.22 - 725.47 |
| 52-Week Range | 507.22 - 832.70 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 856.25 (+18.7%) |
| Est. Earnings Date | Oct 28, 2021 |
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research tech...
Financial Performance
In 2020, BIO's revenue was $2.55 billion, an increase of 10.12% compared to the previous year's $2.31 billion. Earnings were $3.81 billion, an increase of 116.43%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 856.25, which is an increase of 18.68% from the latest price.
News
Bio-Rad to Report Third-Quarter 2021 Financial Results, Thursday, October 28, 2021
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the third...
Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise
Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.
A Trio of Stocks for Growth-Oriented Investors
Growth-oriented investors may want to consider the following stocks since they represent businesses with price-earnings ratios below 20 and recorded significant improvements in trailing 12-month earning...
Bio-Rad (BIO) Upgraded to Strong Buy: Here's Why
Bio-Rad (BIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Rad Laboratories (BIO) Is Up 0.05% in One Week: What You Should Know
Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"
Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Bio-Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that management will partic...
New Analyst Coverage Puts Spotlight on These 5 Stocks
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like NBTB, BIO, RDNT, ABR and CATY.
This Unknown Biotech Has a Secret Weapon for Outsized Returns
Bio-Rad's equity position in a German pharma company is an asset many investors may not realize.
5 Stocks With Recent Price Strength Amid Robust Reopening
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength like VRTV, LCUT, GRIN, CMRE and BIO have a high chance of carrying the momentum forward.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).
5 Stocks to Buy as Analysts Initiate Coverage
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.
Bio-Rad Laboratories: Surging Growth Continues
Bio-Rad Laboratories, Inc. ( BIO , Financial) is maintaining the torrid rate of growth that has made it one of the most exceptional performers of the past half-decade. This year, the life science resear...
Surging Earnings Estimates Signal Upside for Bio-Rad (BIO) Stock
Bio-Rad (BIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.
What Makes Bio-Rad (BIO) a Good Fit for "Trend Investing"
Bio-Rad (BIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Reports Second-Quarter 2021 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the s...
Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad and 10x Genomi...
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Next For Bio-Rad Laboratories Stock After A 10% Rise In A Month?
The stock price of Bio-Rad Laboratories, a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% over the last yea...
Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the secon...